Literature DB >> 10077377

A clinical comparative study between crystalloid and blood-based St Thomas' hospital cardioplegic solution.

M F Ibrahim1, G E Venn, C P Young, D J Chambers.   

Abstract

OBJECTIVE: Myocardial protection with blood cardioplegia during cardiac surgery is increasingly preferred, but few studies have compared the protective effects of crystalloid cardioplegia to the same solution with blood as the only variable. This clinical study compared the protective effects of crystalloid or blood-based St. Thomas' Hospital cardioplegic solution No. 1.
METHODS: Fifty higher risk patients undergoing elective coronary artery bypass surgery, with an ejection fraction less than 40%, were randomly allocated to receive cold (4 degrees C) intermittent crystalloid St. Thomas' No. 1 cardioplegia (n = 25), or a similar blood-based solution (n = 25) with a haematocrit of 10-12%. We determined (1) peri-operative and post-operative arrhythmias, (2) left and right ventricular function (24 h) using the thermodilution technique, (3) left ventricular high-energy phosphate content sampled before ischaemia, the end of ischaemia and the end of bypass.
RESULTS: Pre-operative haemodynamic data, aortic cross-clamp and bypass times were similar in both groups of patients; there was no mortality. At the end of ischaemia there were no differences in ATP content between groups but creatine phosphate was maintained at a significantly (P < 0.007) higher level in the blood-based St. Thomas' cardioplegia group than the crystalloid St. Thomas' cardioplegia group (20+/-2 (SE) vs. 13+/-1 micromol/g dry wt, respectively). Return to spontaneous sinus rhythm was significantly (P = 0.002) increased in the blood-based St. Thomas' cardioplegia group (96%) compared to the crystalloid St. Thomas' cardioplegia group (60%). Early post-operative ventricular dysfunction occurred in both groups, but normal LV function (stroke work index) recovered significantly (P = 0.043) more rapidly (by 2 h) in the blood-based St. Thomas' cardioplegia group of patients.
CONCLUSIONS: In a higher risk (EF < 40%) group of patients undergoing elective cardiac surgery, addition of blood to an established crystalloid cardioplegic solution significantly enhanced myocardial protection by reducing arrhythmias, improving rate of recovery of function and maintaining myocardial high-energy phosphate content during ischaemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077377     DOI: 10.1016/s1010-7940(98)00287-5

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  New insights on the use of del Nido cardioplegia in the adult cardiac surgery.

Authors:  Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Del Nido Cardioplegia-Not Just Kids Stuff.

Authors:  Linda B Mongero
Journal:  J Extra Corpor Technol       Date:  2016-06

3.  Cold crystalloid versus warm blood cardioplegia in patients undergoing aortic valve replacement.

Authors:  Paolo Nardi; Sara R Vacirca; Marco Russo; Dionisio F Colella; Carlo Bassano; Antonio Scafuri; Antonio Pellegrino; Gerry Melino; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Warm blood cardioplegia versus cold crystalloid cardioplegia for myocardial protection during coronary artery bypass grafting surgery.

Authors:  Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Sara R Vacirca; Guglielmo Saitto; Antonino Costantino; Emanuele Bovio; Antonio Pellegrino; Giovanni Ruvolo
Journal:  Cell Death Discov       Date:  2018-02-14

5.  Type of cardioplegic solution as a factor influencing the clinical outcome of open-heart congenital procedures.

Authors:  Michał Sobieraj; Marta Kilanowska; Piotr Ładziński; Irina Garbuzowa; Michał Wojtalik; Jerzy Moczko; Wojciech Mrówczyński
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-06-25

Review 6.  In search of optimal cardioplegia for minimally invasive valve surgery.

Authors:  Sion Russell; Salman Butt; Hunaid A Vohra
Journal:  Perfusion       Date:  2021-06-03       Impact factor: 1.581

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.